Pregled bibliografske jedinice broj: 688162
Acute antibody-mediated rejection of the kidney transplant - experience of a single center in Croatia
Acute antibody-mediated rejection of the kidney transplant - experience of a single center in Croatia // Medicinski glasnik Ljekarske komore Zeničko-dobojskog kantona, 11 (2014), 1; 138-144 (podatak o recenziji nije dostupan, članak, stručni)
CROSBI ID: 688162 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Acute antibody-mediated rejection of the kidney
transplant - experience of a single center in Croatia
Autori
Orlić, Lidija ; sladoje-Martinović, Branka ; Mikolašević, Ivana ; Pavletić-Peršić, Martina ; Bubić, Ivan ; Jelić, Ita ; Rački, Sanjin
Izvornik
Medicinski glasnik Ljekarske komore Zeničko-dobojskog kantona (1840-0132) 11
(2014), 1;
138-144
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, stručni
Ključne riječi
graft rejection ; imunosupresion ; recommendations ;
Sažetak
ABSTRACT Aim To describe the experience of the Department of Nephrology and Dialysis, University Hospital Rijeka, Croatia, in the treatment of patients with acute humoral rejection (AHR) of kidney transplant by using high dose of intravenous immunoglobulin (IVIG) alone and as a first line treatment. Methods Eight kidney transplant recipients in whom the AHR appeared at different time after the transplantation were reported. At the time of transplantation cross-match in all patients was negative for both T and B cells. At the time of presentation, all patients had signs of renal allograft dysfunction and the rejection was proven by biopsy of the kidney transplant with positive C4d- staining and histopathological evidence of antibody- mediated injury. Early rejection was considered within 180 days after the transplantation and the late one 180 days after the transplantation. In two cases plasmapheresis (PAF) with albumin as replacement fluid was performed. Plasma exchange was done with a 35 mL/kg/body weight volume exchange with albumin for six times. Results Acute humoral rejection was classified as early in three patients and in five as late one. In two patients PAF had been performed as the first line treatment. After the completion of PAF, recuperation of severe graft dysfunction was incomplete and in addition IVIG (as a single dose of 2.0 g/kg) was administered to these patients. In six patients IVIG as a single dose of 2.0 g/kg was applied as the first line treatment. Conclusion Usage of high dose IVIG in the treatment of the acute humoral rejection is efficient, safe and relatively well tolerated.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Rijeka,
Klinički bolnički centar Rijeka,
Fakultet zdravstvenih studija u Rijeci
Profili:
Ivana Mikolašević
(autor)
Ivan Bubić
(autor)
Martina Pavletić
(autor)
Lidija Orlić
(autor)
Sanjin Rački
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Scopus
- MEDLINE
Uključenost u ostale bibliografske baze podataka::
- EMBASE (Excerpta Medica)
- MEDLINE